Personal Care Products Safety Act
USA116th CongressS-726| Senate
| Updated: 3/7/2019
Dianne Feinstein
Democratic Senator
California
Cosponsors (11)
Jeanne Shaheen (Democratic)Mazie K. Hirono (Democratic)Margaret Wood Hassan (Democratic)Kirsten E. Gillibrand (Democratic)Kamala D. Harris (Democratic)Angus S. King (Independent)Amy Klobuchar (Democratic)Sheldon Whitehouse (Democratic)Jacky Rosen (Democratic)Susan M. Collins (Republican)Richard Blumenthal (Democratic)
Health, Education, Labor, and Pensions Committee
- Introduced
- In Committee
- On Floor
- Passed Chamber
- Enacted
Personal Care Products Safety Act This bill authorizes the Food and Drug Administration (FDA) to take various actions with respect to the regulation of cosmetics, such as collecting fees from manufacturers and distributors to fund cosmetics safety activities. The bill also authorizes the FDA to suspend the distribution of products that have a reasonable probability of causing serious adverse health consequences.
View Full TextSuggested Questions
Get AI-generated questions to help you understand this bill better
Timeline
Introduced in Senate
Read twice and referred to the Committee on Health, Education, Labor, and Pensions. (Sponsor introductory remarks on measure: CR S1742)
Health
Animal protection and human-animal relationshipsBusiness recordsCoalCongressional oversightConsumer affairsCosmetics and personal careDepartment of Health and Human ServicesDrug safety, medical device, and laboratory regulationEmployee hiringFederal preemptionFood and Drug Administration (FDA)Government employee pay, benefits, personnel managementGovernment information and archivesInflation and pricesLicensing and registrationsManufacturingProduct safety and qualitySmall businessState and local government operationsUser charges and fees
Personal Care Products Safety Act
USA116th CongressS-726| Senate
| Updated: 3/7/2019
Personal Care Products Safety Act This bill authorizes the Food and Drug Administration (FDA) to take various actions with respect to the regulation of cosmetics, such as collecting fees from manufacturers and distributors to fund cosmetics safety activities. The bill also authorizes the FDA to suspend the distribution of products that have a reasonable probability of causing serious adverse health consequences.
View Full TextSuggested Questions
Get AI-generated questions to help you understand this bill better
Timeline
Introduced in Senate
Read twice and referred to the Committee on Health, Education, Labor, and Pensions. (Sponsor introductory remarks on measure: CR S1742)
Dianne Feinstein
Democratic Senator
California
Cosponsors (11)
Jeanne Shaheen (Democratic)Mazie K. Hirono (Democratic)Margaret Wood Hassan (Democratic)Kirsten E. Gillibrand (Democratic)Kamala D. Harris (Democratic)Angus S. King (Independent)Amy Klobuchar (Democratic)Sheldon Whitehouse (Democratic)Jacky Rosen (Democratic)Susan M. Collins (Republican)Richard Blumenthal (Democratic)
Health, Education, Labor, and Pensions Committee
Health
Related Bills
- Introduced
- In Committee
- On Floor
- Passed Chamber
- Enacted
Animal protection and human-animal relationshipsBusiness recordsCoalCongressional oversightConsumer affairsCosmetics and personal careDepartment of Health and Human ServicesDrug safety, medical device, and laboratory regulationEmployee hiringFederal preemptionFood and Drug Administration (FDA)Government employee pay, benefits, personnel managementGovernment information and archivesInflation and pricesLicensing and registrationsManufacturingProduct safety and qualitySmall businessState and local government operationsUser charges and fees